Trial Profile

A Phase III, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Superiority of STN1013800 Ophthalmic Solution 0.1% Compared with Placebo Ophthalmic Solution in Subjects with Acquired Blepharoptosis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Jan 2026 New trial record
08 Jan 2026 According to RVL Pharmaceuticals media release, Santen Pharmaceutical has obtained the manufacturing and marketing approval in Japan for UPNEEQ Mini Ophthalmic Solution 0.1% (generic name: oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids).
22 Dec 2025 According to Santen Pharmaceutical media release, company has obtained manufacturing and marketing approval in Japan for UPNEEQ Mini Ophthalmic Solution, a treatment for acquired blepharoptosis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com